NCT05078255

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Asger Lund, MD · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

Due to reports of a severely reduced insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable in T2D. Recently, however, tirzepatide, a novel dual incretin receptor agonist (activating both the GIP receptor and the glucagon-like peptide 1 (GLP-1) receptor) demonstrated massive improvements in glycaemic control and robust body weight losses; greater than observed with the GLP-1 receptor agonist semaglutide. However, the contribution of GIP receptor activation to these effects remains unknown. The present study will evaluate the glucose-lowering effect of GIP in the context of pharmacological GLP-1 receptor activation in patients with T2D.

Conditions

• Type 2 Diabetes
• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide 1.34 MG/ML [Ozempic]	Semaglutide 1.34 mg/ml
DRUG	Glucose-dependent insulinotropic polypeptide (GIP)	GIP
OTHER	Semaglutide 1.34 mg/ml placebo	Saline
OTHER	GIP placebo	Saline

Timeline

• Start date: 2022-01-27
• Primary completion: 2025-01-06
• Completion: 2025-01-24
• First posted: 2021-10-14
• Last updated: 2025-03-14

Locations

1 site across 1 country: Denmark